GAIA and MEDICE Sign Licensing Agreement for the Commercialization of attexis® for Adults with ADHD in Germany

GAIA, a global leader in the development of digital therapeutics, today announced the signing of a licensing agreement for attexis® with MEDICE Arzneimittel Pütter GmbH & Co. KG (MEDICE – The Health Family). As one of the market-leading pharmaceutical companies in ADHD treatments, the MEDICE Health Family will leverage its market know-how and its commercial scale for attexis® in Germany.

attexis® is a personalized, fully-automated digital therapy designed to help adult ADHD patients better manage their symptoms. Its efficacy and safety are currently being studied in a large-scale clinical trial (RCT).

Under the agreement, MEDICE will receive exclusive rights to commercialize attexis® in Germany, aiming to expand access to this innovative digital therapy. Both companies will collaborate closely to ensure that attexis® is made available to ADHD patients across Germany as soon as possible.

“We are very excited about the partnership with the MEDICE Health Family,” said Dr. Mario Weiss, CEO of GAIA. “MEDICE's extensive expertise in ADHD treatment and commitment to innovative healthcare solutions align perfectly with GAIA’s mission to provide cutting-edge, clinically effective digital therapeutics. Together, we believe attexis® will be a ground breaking option for adult ADHD patients, as well as for physicians and therapists.”

This collaboration reflects the shared commitment of GAIA and the MEDICE Health Family to advance mental healthcare in Germany. Both companies will leverage their combined expertise in digital health and pharmaceutical commercialization to ensure access to attexis® in Germany. attexis® is expected to be available to all physicians and therapists as a prescribable therapy under the DiGA process in the first half of 2025.

“We are proud to partner with GAIA in one of our key indication areas, ADHD treatment,” says Dr. Dr. Richard Ammer, Managing Partner of MEDICE. “With the increasing prevalence of ADHD and the growing demand for innovative treatment solutions, attexis® as an innovative digital therapeutic represents a significant advance in multimodal therapy and thus fits very well into our product portfolio. We look forward to driving the availability and success of attexis® on the German market,” adds Dr. Katja Pütter-Ammer, Managing Partner of MEDICE.

“The strategic partnership is an important milestone in the MEDICE Health Family's efforts to create new offerings for our patients by further expanding the portfolio of complementary pharmacological and non-pharmacological interventions that open up new treatment paths for prescribers,” said Dr. Felix Lambrecht, Managing Director Medigital.